- Active not recruitingPHASE3
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
This study looks at a new medicine called asciminib for adults with a type of blood cancer called CML. Researchers want to see if it works better than other standard CML treatments. It's for people recently diagnosed who haven't had treatment yet.
For: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome PositiveUnited States · Australia · Austria - RecruitingPHASE4
Asciminib Roll-over Study
This study is for people who have already been taking a medicine called asciminib (or similar drugs) in a Novartis study for a type of blood cancer called CML. It allows them to keep taking the medicine if their doctor thinks it's still helping them.
For: Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, BCR-ABL PositiveUnited States · Argentina · Austria - Active not recruitingPHASE3
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
This study compared two oral medications, asciminib and nilotinib, for adults newly diagnosed with a type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (CML). It looked at how well people tolerated each drug.
For: Philadelphia Chromosome-Positive Chronic Myeloid LeukemiaUnited States · Argentina · Bulgaria - Active not recruitingPHASE2
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
This study looks at whether people with Chronic Myeloid Leukemia (CML) can successfully stop their nilotinib medicine a second or third time if their cancer has been well-controlled for a long time. It focuses on those who previously tried and weren't able to stop permanently.
For: Chronic Myeloid LeukemiaGermany · Netherlands